Juno Therapeutics, Inc. of SEATTLE, WA, a company, filed a Form D exempt-offering notice with the SEC on 2014-08-14. The offering totals $133.7M, of which $85.5M was reported sold. Industry: Biotechnology.
Showing 25 of 33 people.
| Name | Role | Location |
|---|---|---|
| Anthony Evnin | Director | Cambridge, MA |
| Richard Klausner | Director | South San Francisco, CA |
| Robert Nelsen | Director | Seattle, WA |
| Howard Pien | Director | Harrison, NY |
| Marc Tessier-Lavigne | Director | Seattle, WA |
| Bernard Cassidy | Executive Officer | Seattle, WA |
| Richard Klausner | Promoter | South San Francisco, CA |
| Robert Nelsen | Promoter | Seattle, WA |
| Mark Frohlich | Executive Officer | Houston, TX |
| Mark Frohlich | Promoter | Houston, TX |
| Robert Azelby | Executive Officer | Redmond, WA |
| Mary Agnes Wilderotter | Director | SAN FRANCISCO, CA |
| Robert J Nelsen | Director | SEATTLE, WA |
| Robert J Nelsen | Promoter | SEATTLE, WA |
| HANS BISHOP | Director | MENLO PARK, CA |
| HANS BISHOP | Executive Officer | MENLO PARK, CA |
| HANS BISHOP | Promoter | MENLO PARK, CA |
| Howard J Pien | Director | Corte Madera, CA |
| Hal J Barron | Director | Seattle, WA |
| Richard J Klausner | Director | Seattle, WA |
| Richard J Klausner | Promoter | Seattle, WA |
| Anthony J Evnin | Director | Seattle, WA |
| Sunil Agarwal | Executive Officer | Seattle, WA |
| Steven Harr | Executive Officer | Seattle, WA |
| Thomas Agnes Daniel | Director | Seattle, WA |
| Filed | Form | Offering | Sold |
|---|---|---|---|
| 2017-10-05 | D | $31.1M | $31.1M |
| 2017-06-29 | D/A | — | $898.5M |
| 2016-07-06 | D/A | — | $896.8M |
| 2015-07-14 | D | — | $849.8M |
| 2014-05-08 | D | $97.0M | $28.4M |
| 2013-12-26 | D | $7.1M | $6.7M |